Can answer just one of your many questions, doc.

Quote:

---

> Analysts project that Rezdiffra's sales will continue to grow, with estimates of $78.3 million for 2024, increasing to $478.5 million in 2025, and reaching $1.245 billion in 202[6/quote]

But that doesn't cover the market, GPT says:

Quote:

---

Looking further ahead, some analyses suggest that the MASH treatment market could reach up to $20 billion by 2032, reflecting the substantial unmet medical need and the ongoing development of new therapies

---

If we are negotiating with a company about the indication, I trust that Jay would make sure to include a healthy percentage cut.....

---